|Brand name(s), other common name(s)||Xgeva®|
|Drug type||RANK ligand (RANKL) inhibitor|
|How the drug is given||Subcutaneous (SC) injection|
Indications and Usage
Denosumab is FDA approved for the prevention of skeletal-related events in patients with multiple myeloma.
Side effects needing medical attention
For multiple myeloma patients receiving denosumab, the most common adverse reactions were diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, rash, and headache.
The most common serious adverse reaction was pneumonia..
Side effects needing medical attention after stopping this medication
The most common adverse reaction resulting in discontinuation of denosumab was osteonecrosis of the jaw.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.